Table 1.
Baseline (before antiviral therapy) characteristics of all SVR (HCC + non-HCC) patients.
| Total = 1241 | HCC n = 54 | Non-HCC n = 1187 | P value | |
|---|---|---|---|---|
| Age (yr) | 50.2 ± 12.6 | 58.3 ± 8.0) | 49.8 ± 12.6 | <0.001 |
| Male sex (n, %) | 559 (45.0) | 26 (48.1) | 533 (44.9) | 0.742 |
| BMI (kg/m2) | 23.6 ± 3.2 | 24.0 ± 3.2 | 23.6 ± 3.2 | 0.403 |
| NAFLD (n, %) | 317 (25.5) | 25 (46.3) | 292 (24.6) | 0.001 |
| HCV Genotype (%) | 0.432 | |||
| 1b | 894 (72.0) | 43 (79.6) | 851 (71.7) | |
| 2a | 323 (26.0) | 10 (18.5) | 313 (26.4) | |
| others | 24 (1.9) | 1 (1.9) | 23 (1.9) | |
| HCV RNA (Log10 IU/ml) | 6.0 ± 1.1 | 6.1 ± 1.1 | 6.0 ± 1.1 | 0.484 |
| ALT (U/L) | 74.9 ± 15.7 | 73.2 ± 15.5 | 75.0 ± 15.7 | 0.392 |
| TBIL (μmol/L) | 20.6 ± 9.2 | 23.4 ± 7.4 | 20.5 ± 9.2 | 0.023 |
| CRE (μmol/L) | 74.0 ± 13.8 | 72.4 ± 15.5 | 74.0 ± 13.7 | 0.401 |
| PLT ( × 109/L) | 161.6 ± 63.4± | 145.6 ± 68.0 | 162.4 ± 63.1 | 0.058 |
| Age ≥ 55 yr (n, %) | 483 (38.9) | 37 (68.5) | 446 (37.6) | <0.001 |
| AFP ≥ 20 ng/ml (2 × ULN) | 254 (20.5) | 25 (46.3) | 229 (19.3) | <0.001 |
| Diabetes (n, %) | 116 (9.3) | 18 (33.3) | 98 (8.3) | <0.001 |
| LSM ≥ 14.6 kPa (n, %) | 376 (30.3) | 36 (66.7) | 340 (28.6) | <0.001 |
| Mean LSM (kPa) | 11.1 (7.5–16.0) | 17.4 (13.7–21.3) | 10.8 (7.5–15.3) | <0.001 |
Continuous variables were expressed as mean ± sd and compared using the unpaired, 2-tailed t-test. Categorical variables were presented as numbers and percentages.